PTC Therapeutics, Inc. announced that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.67 USD | -0.05% | -0.63% | +36.68% |
05-24 | Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing | MT |
05-21 | Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.68% | 2.89B | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza